Zydus receives EIR for the API manufacturing facility at Ankleshwar

Zydus Lifesciences Ltd has received the Establishment Inspection Report (EIR) report from the US FDA for the inspection conducted at its API manufacturing facility located at Ankleshwar. This facility underwent an inspection from 10th to 14th March 2025, and the inspection has been classified as No Action Indicated (NAI). The USFDA has concluded that this inspection is "closed".

Zydus receives EIR for the API manufacturing facility at Dabhasa

Zydus Lifesciences Ltd has received the EIR report from the USFDA for the inspection conducted at its API manufacturing facility located at Dabhasa near Vadodara. This facility underwent an inspection from 21st to 25th April 2025 and has been classified as Voluntary Action Indicated (VAI). FDA confirmed the inspection as "closed".